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private sector in Turkey and as of 2009, 71.5% of total dialysis treatment was ad-
ministered by the private sector. The aim of the study is to calculate the average
cost of dialysis seance for Turkey. METHODS: A Cost model was designed with
main costs including pharmaceutical, medical device, personal, financial, depreci-
ation, tax and other cost. 75 dialysis clinics, already audited by international inde-
pendent organizations, were included in the analysis. RESULTS: A total of 7.102
and 7.090 patients were treated, 1.018.712 and 1.028.392 seances were adminis-
tered in the selected clinics in 2009 and 2010, respectively. The total costs were
calculated as 166 million TL and 163 million TL in 2009 and 2010. Personel costs had
the highest share (35.14% and 35.90%) followed by pharmaceutical and medical
device costs ( 27.16% and 26.20%) for 2009 and 2010, respectively. Average seance
costs were calculated as 163.40 TL and 164.07 TL for 2009 and 2010. CONCLUSIONS:
The Social Security Institution reimburses 135 or 145 TL per dialysis seance de-
pending on the treatment. However, as the study results show this reimbursement
rate is below the real cost. This may cause dialysis center‘s not to provide health
care for government reimbursement agency or going to close due the financial
diffuculties. Closing of private centers may efect system especially patients, be-
cause of dialysis treatment was administered mostly by private sector.
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OBJECTIVES: While it is targeted to give the best health care to patients in emer-
gency room (ER), the economic consequences of the management approach should
also be considered seriously. In this report, the comparison between weekdays and
weekends, of the cost of management of the most common cardiovascular reasons
for admission to ER is presented.METHODS:The invoices generated for admissions
within years 2009-2011, to ER with the presenting diagnoses of (1) hypertensive
diseases, (2) heart failure or (3) cerebrovascular diseases were reviewed. Invoices
were prepared in Turkish Liras (TL). Mid-year TL/€ conversion rates were used
(2.1567, 1.9494 and 2.3435 TL/€ in 2009, 2010 and 2011, respectively). The analysis
was performed form the payer’s perspective. RESULTS: For patients with hyper-
tensive diseases (n18,372), average total cost of health care on Saturdays and
Sundays was 15.92€. This figure was 9.6% and 6.9% higher than the total cost on
Monday and the average total cost on weekdays, respectively. The cost of proce-
dures on weekend was 14.69€. This was 8.4% and 4.0% higher than the cost on
Monday and than the average cost on weekdays, respectively. Average cost of
medications on weekend was 1.00€. This was 16.7% and 48.0% higher than the cost
on Monday and than the average cost on weekdays, respectively. Total costs on
weekends were also higher than on Mondays (and weekdays average) in other
diseases; 46% (38%) for heart failure and 5% (3%) for cerebrovascular diseases.
CONCLUSIONS: The cost of management was higher on weekends than weekdays
for cardiovascular diseases with different nature of courses. Therefore we suggest
that this amount of change in cost in ER is not related with the clinical parameters.
The reason for this high weekend cost might be inappropriate use of health care on
weekends, because the support and supervision of the multidisciplinary approach
are weakened on weekends.
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OBJECTIVES: To evaluate the activity of the outpatient care physiotherapy services
in Hungary, according to the International Classification of Diseases (ICD) code
system. METHODS: Data were derived from the countrywide database of Hungar-
ian Health Insurance Administration (HHIA), based on official reports of outpatient
care institutes in 2008. The total number and the distribution of physiotherapy
services were evaluated according to all of 21 ICD code groups for the year 2008. The
different types of treatment codes are listed in the chapter of the Guidelines of
HHIA for ‘Physiotherapists, massage-therapists, conductors and other physiother-
apy practices’. RESULTS: The total number of physiotherapy services provided in
2008 was 28943680 interventions, of which the 20 most frequent treatments ac-
counts for 72.03 % (20848928) of total services. The three ICD groups with the
highest number of cases were found as the followings: 1) Diseases of the muscu-
loskeletal system and connective tissue (60.74%); 2) Injury and poisoning (10.50%);
and 3) External causes of morbidity and mortality (6.29%). CONCLUSIONS: The
physiotherapy services occurred with the highest incidence in cases of the ‘dis-
eases of the musculoskeletal system and connective tissue‘ ICD group. Therefore,
authors suggest structuring the health care system and distributing resources to
follow the needs supported by our findings.
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OBJECTIVES: Home-Based Management of Malaria (HBMM) is one of the key strat-
egies to reduce the burden of malaria for vulnerable populations in endemic coun-
tries. The strategy seeks to allow caregivers to have immediate health care from
some selected and trained community members. The study sought to identify the
cost drivers of presumptive malaria treatment and cost of seeking care from the
community medicine distributors (CMDs). METHODS: A cross-sectional study was
done in the Ejisu-Juaben Municipality in the Ashanti Region. The study involved
randomly selected 400 caregivers, (10) health staff and (90) community-based med-
icine distributors (CMDs). Structured questionnaires were employed to collect
these data. Data was analyzed into descriptive statistics with SPSSS version 17
software. Test for associations were done at 95% confidence interval. RESULTS:
With the assumption that transport cost and food cost were zero (0) in HBMM, the
cost of treatment of malaria for children between 6-11 months ranged from
GH#P0.01-1.00 ( 0.19 STD), while children between the ages of 12-24 months
ranged from GH#1.00-1.50 (0.04 STD) and 36-59 months ranged from GH#2.00-3.00
(0.30 STD). Generally cost was described as affordable and drivers of treatment
cost were level of severity of the illness, distance to the homes, time spent in
traveling and in the consumer’s homes as well as the number of population within
the CMD’s catchment area. CONCLUSIONS: Cost incurred in accessing HBMM
treatment was affordable to caregivers. Drivers of treatment cost in HBMM varies
from the caregivers and care seekers.
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OBJECTIVES: Despite the fact that the overall incidence of respiratory diseases
tends to decrease, in Ukraine the prevalence of community acquired pneumonia is
high enough: in 2011 it was 494.3 per 100 thousand of the adult population. The aim
of our study was a comparative study of technology inpatient and outpatient treat-
ment of community acquired pneumonia not severe course. Clinical protocol of
Ukraine about treatment of patients with community acquired pneumonia admits
outpatient and inpatient treatment. METHODS: Using the method of cost minimi-
zation we analysed the treatment of patients with not severe community acquired
pneumonia in the course of therapeutic department (1-st group, 120 patients) and
hospital outpatient (2-nd group, 108 patients) under the supervision of physicians
outpatient department. In all cases, the treatment was successful and ended with
recovery of patients.RESULTS:The average duration of treatment of 1-st group was
9,1  1,7 days, second group - 10,4  2,0 days. Total cost of investigation and
treatment of patients in first group was €9,265.49, similar costs in second group was
€4,409.82 (1 EUR  9,98 UAH). Average direct costs of treatment per patient in first
group was €60.65, indirect costs amounted to €16.56. Total cost of treatment per
patient in first group amounted to €77.21. The total cost of treatment per patient in
second group was €40.83, of which direct costs accounted for €30.91, and indirect -
€9.93. Thus, the outpatient treatment of a patient with pneumonia were €36.38
cheaper than inpatient treatment. CONCLUSIONS: The treatment of patients with
community acquired pneumonia in hospital is more expensive than outpatient
treatment. Rise occurs both by indirect and by direct costs.
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OBJECTIVES:As Flanders (Belgium) has an average suicide rate of 1.76 times that in
the EU, prevention of suicide is important to counter the negative consequences
that are associated with suicide and suicide attempts. The objective of this study
was to evaluate the cost-effectiveness of ‘De Zelfmoordlijn’, a suicide prevention
helpline in Flanders.METHODS:An age-, gender- and medium (chat or telephone)-
dependent Markov model with a time horizon of 10 years and a 12-month cycle-
length was developed in order to predict cumulative costs and QALYs (quality
adjusted life years) in a high-risk population. Costs were taken from a societal
perspective. The model consists of six transition states: the initial phase, first non-
fatal attempt, non-fatal re-attempt, follow-up, fatal attempt and death of other
causes. A scenario with the existence of the helpline was compared with a scenario
without its existence. The effect of the helpline was derived from published liter-
ature. Uncertainty was taken into account by carrying out one-way and probabi-
listic sensitivity analysis. RESULTS: Over a period of 10 years, it is estimated that
35% of suicides and suicide attempts can be avoided in this high-risk population,
due to the suicide helpline. By means of the chat sessions and telephone service ‘De
Zelfmoordlijn’ increased average QALYs respectively by 0.057(-0.029-0.143) and
0.099 (0.050-0.148) for men and by 0.034 (-0.015-0.081) due to the telephone service
in women. The chat service led to a QALY neutral result in women (-0.002; -0.097-
0.093). The total costs decreased, resulting in net societal savings in men of €2652
(€2094-€3521) for the chat service and €2010 (€1600-€2444) for the telephone service
and in women of €1930 (€1408-€2489) and €1496 (€1116-€1910) respectively.
CONCLUSIONS: This modeling exercise predicts that ‘De Zelfmoordlijn’ is a cost-
effective, net saving, intervention to prevent suicide in a high-risk population.
PHS39
COST-EFFECTIVENESS OF A NURSE-LED INTEGRATED CHRONIC CARE
APPROACH VERSUS USUAL CARE IN PATIENTS WITH ATRIAL FIBRILLATION
Hendriks JM1, Tomini F2, Van asselt AD2
1Maastricht University Medical Centre, Maastricht, Limburg, The Netherlands, 2Maastricht
University Clinical Center, Maastricht, Limburg, The Netherlands
OBJECTIVES: A recent randomized controlled trial has demonstrated significant
reductions in terms of cardiovascular hospitalizations and deaths with a nurse-led
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integrated chronic care approach in patients with atrial fibrillation compared to
usual care. The objective of the present study is to assess cost-effectiveness of this
nurse-led care program versus usual care.METHODS:A cost effectiveness analysis
was undertaken alongside the randomized controlled trial in which 712 patients
were included at the Maastricht University Medical Centre, Maastricht, The Neth-
erlands, and allocated to nurse-led care or usual care. Nurse-led care implied
guideline adherent management, steered by dedicated software and supervised by
cardiologists. Usual care was regular outpatient care performed by cardiologists. A
cost per lifeyear as well as a cost per QALY analysis was performed, both from a
hospital perspective. QALYs were based on scores of the Short Form 36 question-
naire (SF-36), converted to utility scores by extracting the Short Form 6D (SF-6D). All
unit prices were supplied by the hospital’s financial department, except for prices
for medication, which were taken from the Dutch Pharmacotherapeutic Compass.
Results represented the costs and effects for a 12 months follow-up period.
RESULTS: The nurse-led care program was associated with slightly more lifeyears
and QALYs at a lower cost. Specifically, the nurse-led program contributed to 0.086
QALY gains with a reduced cost of € 1102.77 per patient and a gain of 0.02 life years
with a reduced cost of € 731.62 per patient. Therefore, the nurse-led program would
be considered dominant. In fact, for all the possible values of willingness to pay for
a QALY the nurse-led program is considered to be more likely cost effective than
the care as usual. CONCLUSIONS: The cost-effectiveness analysis in the present
study demonstrated that a nurse-led integrated care approach is very likely a cost-
effective management strategy for patients with atrial fibrillation.
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OBJECTIVES: To demonstrate the lowest expected cost of the interventions for the
treatment of insomnia in elderly after considering the various costs and utilities
associated with adverse events; falls in particularly using a decision tree.
METHODS: A decision tree was used to estimate the lowest expected cost and
cost-effectiveness of two interventions with untreated elderly population suffering
from insomnia. The economic analysis estimates the average total cost of treat-
ment with benzodiazepines and cognitive behavioural therapy plus the cost asso-
ciated with adverse events due to benzodiazepines and cognitive behavioral ther-
apy, based on published data sources, and average QALYs lost due to various
adverse events associated with use of benzodiazepines.Incremental cost-utility
ratio (ICUR) was calculated to estimate the additional costs of cognitive behavioural
therapy (over benzodiazepines) associated with the use of cognitive behavioural
therapy to achieve a gain of one additional QALY (over benzodiazepines). RESULTS:
Ranking analysis of different strategies revealed that cognitive behavioural ther-
apy is 33% cheaper with an incremental value of CAD$725.13 compared to un-
treated insomnia and 56% cheaper with an incremental value of $1158.81 com-
pared to benzodiazepines treatments. Cognitive-behavioral therapy was the
clearly in dominance and dominate bezodiazepines with an ICER of -46520 and
untreated insomnia with an ICER of -27251. Monte-carlo probabilistic sensitivity
analysis shows the cognitive behavioral therapy as the optimal strategy with a net
monetary benefit of CAD$30809.40. CONCLUSIONS: This case example using in-
somnia and the risk of falls in the elderly demonstrates that current treatment
reimbursement options that fund pharmacologic but not non-pharmacologic ther-
apy for geriatric insomnia are neither cost-saving nor ethically recommendable
from the health system’s perspective.A major restructuring of decision-making
processes for reimbursement of treatment options for chronic non-life threatening
conditions is required that considers age-related adverse treatment effects
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OBJECTIVES: We conducted a cost-effectiveness analysis (CEA) on two strategies:
routine HIV counseling and testing (RCT) and home-based HCT (HBHCT) in
Kayunga District, Uganda. METHODS: A decision-analytic model was developed to
evaluate the cost-effectiveness of RCT and HBHCT for provision of HCT to the
population between 2008 and 2010. The reference case was a 30-year old woman in
Kayunga District and the provider perspective was adopted. Costs for HCT were
obtained from project records (MUWRP) and the main outcome measure (effective-
ness) was the number of people who got to know their HIV sero-status in the review
period. Data were analyzed using Tree-age Pro 2011®software. RESULTS: Of 68,650
clients who underwent RCT strategy, only 49.7% (34,138) received their HIV test
results. For HBHCT, 45,000 clients were counseled and tested and 70.6% (31,813)
received their HIV test results. The probability of counseling and testing a HIV
positive client was 0.11 for RCT and 0.03 for HBHCT. The unit cost of providing HCT
was $4.39 for RCT and $10.45 for HBHCT. RCT had an incremental cost of $4.60 and
an incremental cost effectiveness ratio of $15.10 per individual offered HCT.
CONCLUSIONS: In this study, RCT was the more cost-effective strategy. However,
HBHCT was more effective in terms of reaching out to more people who get to know
their HIV sero-status. Basing on the findings of this study, RCT should be prioritized
in all health centers while targeting HBHCT for high burden and hard to reach
settings.
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OBJECTIVES: To assess cost-effectiveness of infant vaccination with 10-valent
pneumococcal non-typeable Haemophilus influenzaeprotein-D conjugate vaccine
(PHiD-CV) or 13-valent pneumococcal conjugate vaccine (PCV13) versus no vacci-
nation in Russia. METHODS: The analysis was performed for a 10-year and a life-
time horizons from health care and societal perspectives. In the analysis only the
direct effect of vaccination was assessed. The effect on invasive pneumococcal
diseases (meningitis, bacteriemia), community acquired pneumonia and pneumo-
coccal acute otitis media (AOM) was evaluated for both vaccines. The effect of
PHiD-CV on AOM caused by non-typeable Haemophilus influenzae was also con-
sidered. Medical costs were estimated based on tariffs of obligatory medical insur-
ance in Saint-Petersburg in 2012. Vaccine cost/dose and schedule of infant vacci-
nation (two doses followed by booster dose) were assumed to be the same for both
vaccines. Indirect costs included illness allowance and productivity losses. Costs
and health benefits were discounted at 3.5%/year. Willingness to pay threshold was
assumed as 1 GDP/capita (approximately 380 KRUB). Sensitivity analysis was con-
ducted on main parameters (incidence data, vaccines effectiveness, costs).
RESULTS: The research showed that incremental cost-effectiveness ratios (ICERs)
for both vaccines are very close. Considering health care perspective ICERs for
PHiD-CV and PCV13 were 376.5 and 383.3 KRUB/1 life year gained (LYG) respectively
at 10-year horizon; 89.1 and 91.1 KRUB/1 LYG at a lifetime horizon. Considering
societal perspective ICERs were 312.6 and 333.3 KRUB/LYG for PHiD-CV and PCV13
respectively at 10-year horizon; both vaccines were shown to be dominating alter-
natives at a lifetime horizon. Sensitivity analysis indicated that results were more
sensitive to incidence data and costs. CONCLUSIONS: Vaccination of infants in
Russia with PHiD-CV and PCV13 is cost-effective at a 10-year horizon. PHiD-CV in
base case analysis had a little bigger potential cost offset compared to PCV13. Both
vaccines could be recommended for inclusion in the Russian national immuniza-
tion calendar.
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OBJECTIVES: Treatment with antiepileptic drugs is commonly guided by serum
level monitoring. Such monitoring requires expensive laboratory equipment and
products. However, well-conducted studies on the cost-effectiveness of therapeu-
tic drug monitoring for antiepileptic drugs are lacking particularly in patients with
structural-metabolic epilepsy. Moreover, there are contradictory thoughts on the
importance of using serum-level monitoring to optimise antiepileptic drugs ther-
apy. The study aims to assess the cost-effectiveness of serum level monitoring
services in the management of children diagnosed with structural-metabolic
epilepsy. METHODS: A retrospective cost-effectiveness analysis was conducted
from the provider perspective. It included patients attended a paediatric neurology
clinic. The effectiveness measures used in this analysis were the number of pa-
tients that achieved 50% reduction in seizure frequency, and the number of pa-
tients with 3-month seizure free. Medical records of the patients were reviewed for
the required information. Medical chart/billing data obtained from the hospital
were collected to estimate the resources used. The recruited children were fol-
lowed for one year following their first visit. RESULTS: The average cost effective-
ness ratio for the monitored patients (MYR 2,735 per patient that achieved a 50%
reduction in seizure frequency) was lower than that for non-monitored patients
(MYR 2,921 per patients that achieved a50% reduction in seizure frequency), with
incremental cost-effectiveness ratio of MYR 2,357 per one additional patient that
achieved a 50% reduction in seizure frequency. The average cost effectiveness
ratios for monitored and non-monitored group were MYR 8,279 and MYR 6,433 per
patient with a 3-month seizure-free period, respectively, with incremental cost-
effectiveness ratio of MYR 29,666 per one additional patient with a 3-month sei-
zure-free period. CONCLUSIONS: In terms of the effectiveness measures used,
serum level monitoring of antiepileptic drugs was found to be cost-effective. How-
ever, the incremental cost-effectiveness ratio was found to be sensitive to the cost
of management.
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OBJECTIVES: Universal hepatitis B vaccination policy has not been introduced in
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